---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053979"
form_type: "8-K"
ticker: null
cik: "0001693011"
company_name: "Inozyme Pharma, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T19:02:05.060068+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inozyme Pharma Q1 net loss $23.3M ($0.38/sh); cash $166.2M; positive ABCC6 data

## Summary
- Net loss $23.3M ($0.38 loss per share) vs $17.4M ($0.40) year ago.
- Cash, cash equivalents, and short-term investments $166.2M as of March 31, 2024; expected to fund operations into Q4 2025.
- Positive topline safety, immunogenicity, and clinical improvement data for INZ-701 in adults with ABCC6 Deficiency reported in April 2024.
- Plan to initiate pivotal trial in pediatric ABCC6 Deficiency in Q1 2025, subject to regulatory review and funding.
- Interim data from SEAPORT-1 (calciphylaxis) on track for Q4 2024; ENERGY-1 (ENPP1 infants) interim data expected 2H 2024.

## SEC filing metadata
- accession: 0000950170-24-053979
- form_type: 8-K
- cik: 0001693011
- company_name: Inozyme Pharma, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1693011/000095017024053979/0000950170-24-053979-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1693011/000095017024053979/inzy-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053979
- JSON: https://secwatch.observer/filing/0000950170-24-053979.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053979.txt

## Key facts
- Earnings Releases
  Inozyme Pharma, Inc. reported the first quarter ended March 31, 2024 results: net income $23.3 million, EPS $0.38 loss per share.
  - Period: the first quarter ended March 31, 2024
  - Net income: $23.3 million
  - EPS: $0.38 loss per share
  - Result: reported results
  source text: Net loss was $23.3 million, or $0.38 loss per share, for the quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1693011/000095017024053979/0000950170-24-053979-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.